Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.
Investor's Business Daily on MSN2h
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss DrugsThe Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback